Sunil John co-wrote this post with Sarah Jarvis
Over the years, pharmaceutical companies’ medical affairs organizations have continued to grow not only in size but also in scope. Now, medical affairs groups are being leveraged as key strategic partners, and they’re being tapped for everything from generating real-world evidence to engaging patient advocacy groups to HEOR research. As a result, pharma companies are increasing their investment in medical affairs organizations: ZS’s 2018 Medical Affairs Outlook Report, which surveyed more than 100 medical affairs personnel from 45-plus companies,
The person who will live to be 150 has already been born, thanks to continuing advances in health care. It’s staggering to contemplate—at the turn of the 20th century, the average lifespan in the United States was just 47. The life sciences industry is responsible for much of this increase in longevity. By nature, life sciences and health care are dynamic, and advances over the next decade have the potential to transform health care as well as the pharma industry. Companies that can spot and capitalize on these trends will enjoy long-term competitive advantages. So here’s a quick look around the corner.